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Abstract 
  Almost 4% of all patients with venous thrombosis have upper extremity deep vein thrombosis 
(UEDVT) and the incidence of UEDVT increases over time. The frequency of post-thrombotic 
syndrome (PTS) after UEDVT is not low and upper extremity PTS is a potentially major 
morbidity that adversely affects quality of life, particularly if the dominant arm is involved. We 
discuss briefly the role of thrombolytic therapy in the treatment of upper extremity deep vein 
thrombosis and also the role of systemic thrombolysis in selected patients. 
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Introduction 
A previously healthy, 24-year-old man was referred to 
our hospital with a five-day history of right upper-
extremity pain and swelling. He was a national 
volleyball player and right-handed. He initially 
complained of arm pain and minimal numbness 
during exercise training in the camp. He later 
developed swelling of the right arm. He denied any 
recent trauma, use of IV drugs and indwelling 
catheters, or history of thromboembolism. Physical 
examination on admission was notable for edema 
involving the right upper arm and shoulder. The 
circumference of the right upper arm was 4.5 cm 
more than that of the left arm. Abduction of the right 
arm was painful. Jugular venous pressure was not 
elevated. No dilated superficial or collateral veins 
were seen on the anterior chest wall or shoulder. 
Arterial pulses were intact, and there was no evidence 
for sensory deficit. Duplex ultrasound of the right 
upper extremity revealed acute occlusive thrombus in 
a dilated axillary and brachial vein and also in the 
distal end of the subclavian vein. Clotting studies, 
hematocrit, chest radiograph and the computed 
tomography scan of the chest were normal. 
  We had not access to the catheter-directed 
thrombolysis and the patient was symptomatic despite 
heparin administration during previous five days. The 
patient was a volleyball player and had a low risk for 
bleeding. We decided to use systemic thrombolysis. 
The patient received infusion of 100 units IV t-PA 
followed by IV heparin. The patient's symptoms and
  venous congestion diminished significantly within 
120 minutes of treatment. Thirty hours later the 
patient was asymptomatic and a CT venography 
showed near-complete resolution of the thrombus. 
He experienced no bleeding complications and soon 
was discharged on warfarin. Warfarin was 
administered for 4 months. At one-year follow-up, 
the patient was asymptomatic with no restriction of 
his activity. 
  Almost 4% of all patients with venous 
thrombosis have upper extremity deep vein 
thrombosis (UEDVT).1,2 UEDVT occurs in 0.15% 
of in-patients.3 Thrombosis of the arm is rare and 
has not been investigated as extensively as deep 
venous thrombosis of the leg.4 The incidence of 
deep vein thrombosis in the upper limb is very lower 
than that of the lower extremity. The explanation for 
this discrepancy is multifactorial and may involve 
more than one of the following factors: 1) there is 
no analog in the upper limb to the soleal network of 
the calf; these veins are probably the site of 
thrombus formation for most lower extremity deep 
vein thrombosis; 2) there are fewer and smaller 
valves in the veins of the upper limb; these valves 
may be the site of thrombus formation for most 
venous thrombi; 3) immobilization of the upper 
limb is less likely even in patients with complete bed 
rest; 4) hydrostatic pressure in the arms is less than 
that of the legs; 5) increased fibrinolytic activity is 
present in the venous circulation of the upper limb.5 
  However, the incidence of UEDVT increases over 
time.6-9 The cause is the increasing use of central
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  venous catheters (CVCs), which combined with 
cancer, is the most important cause of UEDVT.10,11 
Besides foreign bodies such as CVCs and pacemaker 
leads, the main reason of upper limb thrombosis is a 
hypercoagulable condition, as induced by stasis in 
veins, coagulation abnormalities, or cancer. The stasis 
can be caused by a variety of conditions such as 
trauma of the arm, effort-related compression of the 
veins or compression caused by the thoracic outlet 
syndrome.1,6,10,12–15 
  UEDVT are divided into two groups: primary 
(includes unprovoked with or without thrombophilia, 
effort related, and thoracic outlet syndrome) and 
secondary (provoked by central venous catheters, 
pacemakers, or cancer); secondary UEDVT accounts 
for 75 to 80% of all cases.16-18 
  Paget in England and von Schrötter in Germany 
described effort vein thrombosis many years ago. 
Effort-induced thrombosis occurs most frequently in 
young men younger than 45 years. Compression of 
the subclavian vein usually develops in young athletes 
with hypertrophied anterior scalene muscle who do 
heavy lifting or abduct their arms. Cervical ribs, long 
transverse processes of the cervical spine, 
musculofascial bands, and clavicular or first rib 
abnormalities are found in these patients.19 It is 
probably the microtrauma to the venous wall that 
activates the coagulation cascade. Also, repetitive 
venous compression can induce fibrous tissue 
formation and constriction in the vein.20 
  Central venous catheter is the most common risk 
factor for UEDVT.3,17,21 Among 208 intensive care 
needed patients with CVCs, 33% showed catheter 
associated UEDVT.22 Several factors can be 
important in the thrombus formation; these include 
catheter size, catheter material, multilumen catheters, 
duration of catheterization, composition of infusate, 
and final position of the catheter tip. In one series, all 
catheter related thromboses of the upper limb were 
associated with large-size catheters.23 Catheter 
composition is important; for example, silicone 
elastomer catheters are less thrombogenic than 
polyvinyl chloride catheters.24,25 The agents being 
infused, including amino acids, osmolality, and PH 
and proper placement of the catheter in the superior 
vena cava, to provide sufficient dilution of the 
infusate, may contribute to the development of a 
catheter induced thrombus. Horattas et al. found that 
65% of catheter-induced thromboses were left 
sided.26 Also, among one hundred patients with CVCs 
for dialysis, Schillinger et al. found 42% subclavian 
vein stenoses and only 10% jugular veins stenoses.27 
So, the right internal jugular vein should be the 
primary site for CVCs because the risk of stenosis and 
thrombosis is lower. 
  In one study, in one fourth of patients with 
idiopathic UEDVT, malignancies (most commonly 
lung carcinoma or lymphoma) were discovered during 
the follow-up period. Most of these cancers were 
diagnosed during the first week of evaluation for the 
venous thrombosis.28 
  There are limited data about the prevalence of 
prothrombotic abnormalities in patients with 
UEDVT, but studies in patients with lower-extremity 
DVT showed an overall rate of thrombotic disorders 
ranging from 30% to 40%.29 The prevalence of 
coagulation abnormalities in patients with primary 
UEDVT in recent reports has been more than hat in 
previous reports.14,15,18,30 
Clinical Manifestations 
Symptoms can be intermittent, or can develop during 
up to one week.31 UEDVT may involve the 
subclavian, axillary or brachial veins. Physical 
examination may show low-grade fever due to 
thrombus formation. Higher fevers are seen with 
septic thrombophlebitis or in patients with associated 
malignancy. SVC syndrome decreases venous return 
to the heart and may cause sinus tachycardia. Patients 
with UEDVT may have mild cyanosis of the same 
extremity, a palpable tender cord, limb edema, 
supraclavicular fullness, jugular venous distension, 
and dilated cutaneous collateral veins over the chest 
or upper arm.13,32 If there is a central venous catheter, 
one or multiple ports may be occluded.33 
  The disease may lead to complications, including 
pulmonary embolism (PE), recurrent UEDVT and 
post-thrombotic syndrome (PTS) of the arm and also, 
loss of vascular access. 
  The frequency of PE in patients with UEDVT 
ranges from 0 to 36% but it is up to 50% in the 
proximal lower extremity deep vein 
thromboses.16,18,34,35 Fatal PE in the UEDVT is rare.13 
Catheter withdrawn is a risk factor for PE. As catheters 
are removed, fibrin sheaths may peel off the catheter, 
separate from the vessel wall, and induce PE.33 
  Upper-extremity PTS can be a disabling condition 
especially if the dominant arm is involved.36 The risk 
of PTS after UEDVT varies from 7-46% (weighted 
average 15%). Residual thrombosis and 
axillosubclavian vein thrombosis probably increase 
and catheter associated UEDVT may decrease the 
risk of PTS.37At present, there is no standardized 
score to assess upper extremity PTS. The modified 
Villalta score is a clinical PTS scale and the patients 
are asked to rate the severity of each of five 
symptoms (pain, pruritus, cramp, heaviness, and 
paresthesia) and a doctor then will evaluate the 
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severity of each of five signs (prominent veins, hyper-
pigmentation, edema, induration, and redness). Each 
symptom and sign was given a value from 0 (absent) 
to 3 (severe). A total score of 5 or higher was 
classified as the presence of PTS, and a score of 15 or 
higher was classified as severe PTS.38 
  DVT recurs less frequently in the upper-
extremities than in the lower extremities.6,39 In a study, 
female sex (adjusted HR [HRadj], 1.8; 95% CI, 0.9 to 
3.9), a first non-subclavian vein thrombosis (HRadj, 
2.0; 95% CI, 0.8 to 2.7), and body mass index 
(BMI)≥25 kg/m2 (BMI 25 to 29 kg/m2: HRadj, 1.6; 
95% CI, 0.7 to 3.8; BMI ≥30 kg/m2: HRadj, 2.7; 95% 
CI, 1 to 7.3) were associated with a higher risk of a 
recurrent thrombosis. A CVC at the time of first 
thrombosis was associated with a reduced risk of 
recurrence (HRadj, 0.2; 95% CI, 0.1 to 1).20 Clearly, 
recurrence rate of the venous thrombosis in the lower 
limbs is higher among men than women.40-44 First 
events in the subclavian vein were showed less 
recurrence than thromboses in other veins of the 
upper extremity. The cause may be the removal of the 
CVC because most CVCs are inserted in the 
subclavian vein.20 
  Patients with an UEDVT have an increased risk of 
death compared with the general population that is 
mainly related to cancer.9,20,45 
Diagnosis 
Venography is the standard method of diagnosis, but 
ultrasonography remains the most available and 
noninvasive test used. 
  Cervical spine and chest plain films are necessary 
to evaluate thoracic outlet syndrome. If thoracic 
outlet syndrome is suspected, the examiner should 
palpate the supraclavicular fossa for brachial plexus 
tenderness, see the hand and arm for atrophy, and do 
some maneuvers (Table 1).13 To perform the Adson 
test, the examiner extends the patient’s arm on the 
affected side while the patient extends the neck and 
rotates the head towards the same side. Decreasing 
the radial pulse with deep inspiration suggests 
compression of the subclavian artery. Wright’s 
maneuver determines the reproduction of symptoms 
and weakening of the radial impulse when the 
patient’s shoulder is abducted and the humerus is 
turned outside.19  
 Coagulation  tests  (lupus  anticoagulant, 
anticardiolipin antibodies, antiphospholipid units for 
IgG and IgM, plasma homocysteine, activated protein 
C resistance, protein S and C deficiencies, 
antithrombin III deficiency, and prothrombin gene 
mutation G20210A) were done at least 2 months after 
the thrombotic event because of possible abnormal 
results due to consumption of natural inhibitors or 
acute phase reaction of thrombosis. Protein C and 
protein S plasma levels were evaluated after 
termination of anticoagulation treatment. 
Management 
There are five methods for the initial treatment of 
DVT: (1) subcutaneous low-molecular weight heparin 
(LMWH), without monitoring; (2) intravenous 
unfractionated heparin (UFH), with monitoring; (3) 
subcutaneous UFH, with monitoring (4); weight-
based subcutaneous UFH, without monitoring; and 
(5) subcutaneous fondaparinux, without monitoring. 
The current recommended approach is to start both 
heparin and vitamin K antagonists, and to stop 
heparin after 5 days if the international normalized 
ratio (INR) is >2.0 for at least 24 h.46 Warfarin can 
usually be started at a dose of 10 mg in younger (< 60 
years), otherwise healthy outpatients, and at a dose of 
5 mg in older or hospitalized patients. Warfarin doses 
should be adjusted to achieve the target INR (range 
2.0 to 3.0).47,48 
  In more than 50% of patients, anticoagulation 
results in symptomatic improvement. However, 
anticoagulation can not remove existent thrombus 
and may not prevent PTS. The clinical improvement 
with anticoagulant treatments may be related more to 
development of collateral veins than resolution of 
thrombus.49 
  For most patients with acute UEDVT, the routine 
use of systemic or catheter-directed thrombolysis is 
not recommended (Grade 1C). In selected patients 
with acute UEDVT who are low risk of bleeding with 
severe symptoms of recent onset, the catheter-
directed thrombolysis (CDT) may be used for initial 
treatment if appropriate expertise and resources are 
available (Grade 2C).46 
  Also, in selected patients with acute UEDVT and 
failure of anticoagulant or thrombolytic treatment 
who have severe persistent symptoms, other methods 
(catheter extraction, surgical thrombectomy, 
transluminal angioplasty, or a staged approach of lysis 
followed by a vascular interventional or surgical 
procedure) can be used if appropriate expertise and 
resources are available (Grade 2C).46 
  In selected patients with acute UEDVT and 
contraindication for anticoagulation with evidence of 
DVT progression or significant PE, filter placement in 
the superior vena cava is recommended (Grade 2C).46 
  For most patients with catheter induced UEDVT, 
catheter removal is not recommended if it is functional 
and necessary (Grade 2C).46 New-site catheter insertion 
has a high rate of new thrombus formation. 50 
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  For patients who have UEDVT in association with 
a central venous catheter that is removed, the duration 
of long-term anticoagulant treatment should not be 
shortened to less than three months (Grade 2C).46 
  No randomized controlled studies have evaluated 
the thrombolytic therapy for the initial treatment of 
patients with UEDVT. But, some studies report good 
results for thrombolytic therapy in terms of early and 
late venous patency.51-53 However, for important 
clinical end points such as PE, recurrent VTE, 
bleeding, and PTS, there is not enough data to see 
whether thrombolytic approach is better than 
anticoagulation or not. 
  The routine use of elastic compression or venoactive 
medications for PTS prevention after UEDVT is not 
recommended. In patients with persistent edema and 
pain, elastic compression to reduce symptoms of PTS is 
recommended (Grade 2C).46 
Systemic Thrombolytic Therapy for Acute 
DVT 
The best candidates for thrombolytic therapy  are 
young, healthy patients with primary UEDVT, 
patients with symptomatic SVC syndrome, and those 
who require preservation of a central venous 
catheter.34  Some trials demonstrated that systemic 
thrombolytic therapy provided a better lysis with 
reduction in post-thrombotic syndrome.54-61 
  There are two recommendations: 1-Some patients 
with extensive proximal DVT (e.g., symptoms for less 
than 14 days, good functional status, life expectancy of 
more than 1 year, and low risk of bleeding) may benefit  
from the systemic thrombolytic therapy to reduce acute 
symptoms and post-thrombotic morbidity if CDT is not 
available (Grade 2C).46 
2-In patients with acute PE, the thrombolytic agent is 
administered via a peripheral vein rather than placing a 
pulmonary artery catheter (Grade 1B).46 
  And, we want to think about systemic thrombolytic 
therapy in selected patients with UEDVT; those patients 
who are low risk for bleeding and high risk for PTS. 
Surgical Therapy versus Stenting 
The standardized protocol for treatment includes 
CDT, a short period of anticoagulation, and selective 
surgical decompression for patients with persistent 
symptoms. Some believe that there is no role for 
stenting of the subclavian vein in the region of the 
thoracic outlet before operative decompression 
because the persistent mechanical forces likely lead to 
stent malfunction and making the situation worse. 
  The young age (<28 years old) and the use of stent 
during initial treatment increase the recurrent rate of 
thrombosis. Thus, younger patients are probably 
suitable for early surgical decompression, and the use 
of stents without thoracic outlet decompression is not 
recommended. Patients who respond to warfarin 
therapy and demonstrate complete resolution of 
symptoms can be offered a non-operative approach 
with acceptable long-term results. Younger patients 
who are potentially more active and might engage 
more rapidly in strenuous activities probably should 
be offered surgical decompression. There are not 
persistent venographic findings that necessitate 
surgical intervention.62 
  There are different strategies from immediate first-
rib resection during the hospitalization to some 
delayed surgery, 3 months later to no surgery at all. 
Indications for the surgery early after thrombolysis 
and the trial of outpatient anticoagulation include (1) 
the persistence or recurrence of venous hypertensive 
symptoms,(2) any evidence for recurrent or new 
thrombus, (3) obstruction of perivenous collaterals 
with abduction/external rotation in the face of 
subclavian vein occlusion, and (4) evidence of 
persistent or recurrent vein damage, as demonstrated 
by significant wall thickening.62 
  The potential benefit of conservative approach 
versus thoracic outlet decompression is to avoid the 
surgical complications, such as brachial plexopathies, 
phrenic nerve paresis, subclavian arterial injuries, and 
lymphatic leaks, with incidences ranging from 15% to 
20%.63 
 
Table 1. Provocative Physical Tests 64 
Diagnostic Test  Maneuver  Positive Test 
Adson 
(scalene) 
The patient inspires maximally and hold his 
or her breath while the neck is fully 
extended and the head is turned toward the 
affected side. 
The loss or decrease of radial pulse or the 
reproduction of neurologic symptoms 
means a positive test. 
Halsted 
(costoclavicular) 
The patient places his or her shoulders in a 
military position (drawn backward and 
downward). 
The loss or decrease of radial pulse or the 
reproduction of neurologic symptoms 
means a positive test. 
Wright 
(hyperabduction)  The patient’s arm is hyperabducted 180°. 
The loss or decrease of radial pulse or the 
reproduction of neurologic symptoms 
means a positive test. 
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Conclusions 
The optimal management of effort-related primary 
upper extremity vein thrombosis is not determined 
because outcomes after different treatment strategies 
are based on isolated case reports and small 
retrospective series. Thus, decision should be 
individualized.  
  The patients are often young people and otherwise 
healthy. Major disability can develop in these patients 
if PTS is occurred. 
  Anticoagulant therapy did not achieve complete 
resolution of the thrombus over months of follow-up. 
Other treatments, including thrombolytic therapy and 
surgical intervention might be indicated in patients 
whose symptoms do not decrease significantly after 
conservative therapy. 
 The catheter-directed thrombolysis provides 
higher clot resolution rates and less systemic side 
effects from systemic thrombolysis. However, it is 
possible to use systemic thrombolytic therapy for 
selected cases with UEDVT. It may be similar to the 
use of systemic thrombolysis in the pulmonary emboli 
or extensive proximal DVT. 
 
Footnote (page 1 or 2): If benefits clearly do or do 
not outweigh harms, burden, and costs, it makes a 
strong Grade 1 recommendation. If there are less 
certainty about the magnitude of the benefits and 
risks, burden, and costs, it makes a weaker Grade 2 
recommendation. 
 
For grading the methodologic quality, randomized 
controlled trials (RCTs) are high-quality evidence 
(designated by “A”), but quality can decrease to 
moderate (“B”), or low (“C”) because of poor design 
and conduct of RCTs, imprecision, inconsistency of 
results, or a high suspicious for reporting bias. 
Observational studies are as low quality of evidence 
(C) but can improve their quality with very large 
treatment effects. 
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